Kornimate/medical-research-clean huggingface dataset:
depression, epinephrine, and platelet function

Conditions: Major Depressive Disorder

Summary: men and women who have suffered sexual and/or physical abuse before the age of 12 are at increased risk for anxiety and mood disorders, other serious psychiatric disorders, and likely medical illnesses. what is not known is whether adult survivors of childhood adversity experience heightened negative emotions and increased physical responses due to altered norepinephrine or serotonin systems in their brains and bodies. the investigators expect to see that survivors of childhood adversity experience heightened negative emotions and increased physical responses to stress.


Eligibility criteria:
inclusion criteria: - exclusion criteria: * individuals who are suicidal, psychotic, or with bipolar depression * alcohol or substance abuse or * regularly use medications which alter mood or blood vessel function (zolpidem or zalpelon, aspirin, nonsteroidal antiinflammatory drugs, sympatholytics, theophylline, central acting agonists, beta-blockers, coumadin, nitrates, triazolobenzodiazapines, or use steroids (testosterone-patch or pill form), use tryptophan or monoamine oxidase inhibitors (maois), * have narrow-angle glaucoma, liver disease, * severe allergies (especially to antidepressants similar to escitalopram or desipramine) * seizures, or a serious medical disorder (e.g. hypothyroidism) that is unstable or is untreated. * depressed patients with a prior history of severe adverse events associated with ssris or tcas will not be accepted into the study.

Keywords: platelet function childhood abuse depression antidepressants immune function stress response
protective step training in parkinson's disease

Conditions: Parkinson Disease

Summary: the primary purpose of this project is to determine the preliminary effectiveness of protective step training to improve balance and reduce falls in people with parkinson's disease (pd) and postural disturbances. a secondary purpose is to understand which baseline patient characteristics predict responsiveness to treatment. by informing 1) the effectiveness of a promising rehabilitative intervention, and 2) the selection of the participants that will be most responsive to treatment, these data may enhance clinicians' ability to treat balance disturbances in people with pd. importantly, protective step training, described in this proposal, can be quickly deployed in the clinic at minimal cost. therefore, if shown to be effective via this and subsequent trials, this approach can be easily integrated into care, immediately impacting a large number of people with pd.

this project contains 3 aims: aims 1 and 2 address the primary goal of this project: determining the effectiveness of protective step training. aim 1 will test whether perturbation training can improve protective stepping in people with pd with postural dysfunction. aim 2 will test whether improvements are retained over 2 months and generalize to untrained perturbation tasks (which may be important for real world situations). importantly, investigators will also gather exploratory data regarding the effect of perturbation training on falls. aim 3 addresses the secondary goal of this project: determining for whom protective step training is most beneficial. aim 3 will relate behavioral factors and neuroimaging outcomes to the magnitude of improvement in protective stepping. all aims will be tested in people with pd who have postural disturbances. to complete these aims, participants will undergo 12 visits to the laboratory over the course of about 5 months. these will include 6 "training visits" over the course of 2 weeks, surrounded by 6 "assessment" visits before and after the training. during assessment visits, investigators will assess the ability to step quickly in response to a loss of balance (e.g. a slip), as well as thinking assessments and, if eligible, investigators will complete an mri. during training visits, investigators will train the ability to step quickly in response to a slip. in this study, participants will serve as their own controls. as such, there is no randomization to multiple groups.

Eligibility criteria:
inclusion criteria: * neurologist diagnosed pd * postural instability / gait dysfunction (pigd) * ability to stand unaided for 5 minutes exclusion criteria: * non-pd related neurological pathology * orthopedic impairments affecting balance

Keywords: balance falls posture cognition training
effects of anticoagulant preventive injection in patients with blood cancer

Conditions: Lymphoma; Multiple Myeloma

Summary: in cancer, the incidence of venous thromboembolism (vte) is particularly high in patients with myeloma, especially when it is de novo and treated with thalidomide, lenalidomide or erythropoietin. curiously, the prevention of vte with lmwh (low-molecular-weight heparin) in myeloma seems no more effective than that achieved with aspirin, while the effectiveness of the latter in the primary prevention of vte has never been demonstrated regardless of the type of population considered. meanwhile, a biological study showed that prophylactic doses of lmwh in patients with different types of cancer did not always optimal reduction of thrombin peak during the 24 hours following the injection of lmwh. these clinical and biological studies lead to the conclusion that patients with myeloma may be resistant to the usual doses of preventive lmwh, which may explain the failure of prevention. initially we intend to investigate whether this resistance to prophylactic doses of lmwh is present in patient's biology and if this resistance is specific to myeloma in hematological cancers. for this, we propose to study the evolution of thrombin generation by thrombinography during 24 hours after subcutaneous injection of 4500 anti-xa iu tinzaparin in 6 patients with de novo myeloma whit high thrombo embolic risk ie treated with thalidomide, lenalidomide or erythropoietin. lmwh is tinzaparin chosen because it does not accumulate in patients with impaired renal function, and has a greater anti-biological activity thrombotic than other lmwh. to assess whether the observed pattern of thrombin generation is particularly multiple myeloma, we will take the same study in 6 patients with aggressive lymphoma and 6 medical patients hospitalized for acute heart and respiratory failure.


Eligibility criteria:
inclusion criteria: 1. body weight between 40 and 100 kg 2. patient: 2a- with multiple myeloma indication with de novo standard treatment thalidomide or lenalidomide or erythropoietin (group 1) 2b- or hospitalized for aggressive lymphoma treated with chemotherapy (group 2) 2c- or older than 40 years and hospitalized at least three days for an acute medical pathology type of acute respiratory or cardiac (group 3) decompensation exclusion criteria: * patient requiring anticoagulant therapy at curative doses * patients with a lower platelet count 80 g / l * subject with a history of heparin-induced thrombocytopenia * subject with a history of hemorrhagic disease * history of severe trauma within 6 weeks prior to enrollment * organic lesion at risk of bleeding * poor renal with creatinine clearance \<30 ml / min * hypersensitivity to tinzaparin * events or bleeding tendencies associated with coagulation disorders * subject on oral anticoagulant * for group 3: presence of hematological malignancy or active cancer

Keywords: endogenous thrombin potential lymphoma multiple myeloma tinzaparin thrombin generation thromboplastin generation tests
flox in combination with cetuximab in first-line treatment of colorectal cancer

Conditions: Metastatic Colorectal Cancer

Summary: the main objective of this trial is to explore the effect of combining an established chemotherapy regimen (flox), based on 5-fluorouracil, folinic acid, and oxaliplatin (eloxatin®), with the egf receptor antibody cetuximab (erbitux®) in first-line treatment of metastatic colorectal cancer. the trial will investigate two regimens of flox plus cetuximab, in which flox is given continuously or intermittently, compared to standard flox without cetuximab.


Eligibility criteria:
inclusion criteria: histology and staging disease: * histological proven adenocarcinoma of the colon or rectum; * at least one measurable metastatic disease * if only one metastatic lesion and no s-cea elevation, histology is mandatory; * availability of tumour sample for egfr assessment. general conditions: * age \>18 and \< 75 years; * who performance status: life expectancy of more than 3 months; * adequate haematological function * adequate renal and hepatic functions * written informed consent exclusion criteria: prior therapy: * no prior chemotherapy for advanced/metastatic disease; * no adjuvant chemotherapy the last 6 months before inclusion; * no previous oxaliplatin; prior or current history: * no current indication for resection with a curative intent; * no evidence of cns metastasis; * no current infection, unresolved bowel obstruction or subobstruction, uncontrolled crohn's disease or ulcerative colitis; * no current history of chronic diarrhoea; * no peripheral neuropathy; * no other serious illness or medical conditions (including contraindication to 5 fu e.g.: angor, myocardial infarction within 6 months, contraindications to monoclonal antibodies); * no past or concurrent history of malignant neoplasm other than colorectal adenocarcinoma within the past five years, except curatively treated non melanoma skin cancer or in situ carcinoma of the cervix; concomitant treatments: * no concomitant (or within 4 weeks before randomisation) administration of any other experimental drug under investigation; * no concurrent treatment with any other anti-cancer therapy; other: * not pregnant, no breast feeding * fertile patients must use adequate contraceptives * not include patients clearly intending to withdraw from the study if not randomised in the willing arm or patients who cannot be regularly followed up for psychological, social, familiar or geographic reasons.

Keywords: metastatic colorectal cancer flox cetuximab
a bioequivalence study of two different dosages of isoniazid tablet formulations in human healthy volunteers

Conditions: Tuberculosis

Summary: the recommended treatment for latent tuberculosis infection for adults is a daily dose of isoniazid 300mg during 6 months. in brazil, isoniazid was formulated as 100 mg tables. the treatment duration and the high pill burden compromised patient adherence to the treatment. the brazilian national programme for tuberculosis requested the development of a new 300mg isoniazid formulation. the aim of the study is to compare the bioavailability of the isoniazid 300mg new formulation and three 100mg tablets of the reference formulation. the study is a randomized, single dose, open label, fasting, two-phase crossover bioequivalence study with a wash out period of 7 days (\>7 half-life) in 28 healthy human volunteers. for the determination of isoniazid in human plasma, the investigators developed and validated a sensitive, simple and rapid hplc-ms/ms method. this will support the strategy adopted by the brazilian national program for tuberculosis for the treatment of latent tuberculosis. the new formulation will increase patients' adherence to the treatment and quality of life. medical doctors in brazil should become aware of the new formulation and the new treatment strategy in order to prescribe the right medication and avoid errors that could result in a high frequency of adverse events. future research studies should evaluate pharmacovigilance, acceptability of the new tablet formulation and its impact on the cure rate.


Eligibility criteria:
inclusion criteria: * healthy men and women * aged between 18 and 50 years * bmi between 18.5 and 29.9 kg/m²
surgical approach in liver hemangiomas

Conditions: Hemangioma Liver

Summary: operations performed for liver hemangioma between january 2017 and december 2018 will be retrospectively analyzed.

operations performed for liver hemangioma at ankara university hospitals will be retrospectively analyzed. patient and disease characteristics including demographics, laboratory tests, imaging studies, type of surgical approach and outcomes including postoperative laboratory tests, record of complications, duration of hospital stay will be reviewed. complications were classified according to clavien-dindo classification. the patients were informed about the surgeries in advance and their informed consents about surgeries and data collection for scientific purposes were obtained. datafile will be anonymized before analysis and original file will be destroyed. outcomes such as complications, hospital stay, blood transfusion and mortality will be compared between groups created according to type of surgery, lesion size, preoperative laboratory values and demographic features. variables for prediction of better outcomes are expected to be discovered.

Eligibility criteria:
inclusion criteria: * patients underwent surgery for liver hemangioma exclusion criteria: * cases lacking of more than 20% of critical data

Keywords: hemangioma liver resection enucleation
combination of curcumin and berberine therapy in the treatment of post acute diverticulitis (sudd)

Conditions: Diverticulitis

Summary: curcumin (cur), an active ingredient of the indian herb rhizoma curcuma longa, has been extensively studied in the context of inflammatory diseases. studies have demonstrated its efficacy in reducing chemically induced colitis in animal models and in humans. berberine is a phytochemical derived from plants such as coptis chinensis, goldenseal and scutellaria. these herbal remedies have been used in both chinese and european medicine for centuries to treat digestive inflammation and infectious diseases. therefore the investigator see a possible dual mechanism of curcumin-berberine (coptis) treatment in sudd patients through both direct anti-inflammatory action and modulation of intestinal microbiome. this data provides basis for investigating an integrative approach to optimize and offer treatment to patients suffering from post ad sudd. the investigator speculate that using a combined gut-directed formulation of curcumin-berberine could benefit this subgroup of patients and improve their clinical symptoms.

the objective of the study is to investigate the efficacy and safety of gut-directed enteric-coated curcumin-berberine (coptis) combination therapy to induce remission in patients suffering from post ad sudd. methods: this will be a two-stage study: stage 1 will comprise an open label single arm exploratory study of 10 patients suffering from post ad sudd investigating oral cur-berberine (coptis) therapy for induction of clinical response. stage 2: if clinical response is achieved in ≥ 3 patients and no significant safety signals will emerge, the investigator will proceed to a prospective pilot randomized placebo-controlled study.

Eligibility criteria:
inclusion criteria: 1. established diagnosis of previous acute diverticulitis (ad) and on-going abdominal symptoms comprising a sudd (left abdominal pain and/or change in bowel habits and bloating) 2. having an active sudd defined by diverticular clinical score (dics) score ≥10. 3. age 18-80 years. 4. able and willing to give written consent - exclusion criteria: 1. patient with non-controlled renal or liver disease, hypertension, cardiovascular disease, cerebrovascular disease, chronic pancreatitis, diabetes mellitus, gallstone disease, uncontrolled migraines or neurological disorders 2. patients with significant laboratory abnormalities, including anemia with hemoglobin \<10, leucopenia (wbc\<4k/mcl), thrombocytopenia (plt\<100k/mcl), abnormal coagulation tests (inr, ptt), or elevation of liver or kidney function tests above the normal values. 3. patient with active infection, sepsis or pneumonia. 4. pregnant or nursing women. 5. unable or unwilling to receive curcumin-berberine (coptis) therapy 6. known allergy to either curcumin or berberine (coptis) -
availability of vitamin d in orange juice

Conditions: Vitamin D Deficiency

Summary: the purpose of this study was to determine whether vitamin d2 and vitamin d3 in orange juice are effective at raising vitamin d levels in the blood and if vitamin d2 and vitamin d3 in orange juice raised blood levels of 25(oh)d as well as vitamin d3 and vitamin d2 supplements.

this study should provide valuable information about the bioavailability of both vitamin d2 and vitamin d3 formulated in orange juice compared to vitamin d2 and vitamin d3 formulated in a pill and taken with water. it is anticipated based on our previous observation that the vitamin d2 and vitamin d3 in orange juice will be at least 50% more effective in raising the blood levels of 25(oh)d than when taken in pill form. this study will evaluate the bioavailability and metabolism of vitamin d2 and vitamin d3 in combination in tablet form. the results should provide important information as to whether a physiologic dose of vitamin d2 has a negative effect on circulating levels of 25-hydroxyvitamin d2 \[25(oh)d2 \] and on 25-hydroxyvitamin d3 \[25(oh)d3\]. results from this study have important implications for expanding the adequate intake (ai) recommendations for vitamin d2 and vitamin d3 for adults.

Eligibility criteria:
inclusion criteria: * male and female adults of all races ages 18 years and older exclusion criteria: * pregnant and lactating women * history of chronic severe liver (as defined by liver function test greater than 2 times upper limit of normal)or kidney disease as defined by a serum creatinine \>2.5. * history of taking a daily supplement that contains 400 or more iu vitamin d2 or vitamin d3 within the past month or taking a pharmacologic amount of vitamin d2 or one of the active vitamin d analogs including zemplar (paricalcitol), dovonex (calcipotriol), hectorol (vitamin d pro hormone) * subjects who are taking orally dilantin or glucocorticoids. * exposure to a tanning bed or tanning on a beach for more than eight hours within the past month. * subjects who drink more than 2 glasses (16 oz) cups of milk a day. * known history of elevated calcium. (\> 10.5 mg% (mg/dl)) * history of intestinal malabsorption (i.e. cystic fibrosis, fat malabsorption syndrome, crohn's disease) * allergies to orange juice * any medical conditions in which it is not advisable to receive one 8 oz. glass of orange juice per day. * currently taking, or having taken less than one month prior to start of study, a prescription vitamin d * unwilling to consent to this trial

Keywords: vitamin d2 vitamin d3 vitamin d orange juice
mindfulness and behavior change to improve cardiovascular health of older people with hiv

Conditions: Hiv; Cardiovascular Diseases

Summary: older people with hiv (opwh) are disproportionately impacted by cardiovascular disease (cvd) attributable to behavioral risk factors, and chronic hiv immune dysregulation resulting inflammation. systemic inflammation is exacerbated by psychological distress via activating the immune response and driving pro-inflammatory cvd risk behaviors. there is promising evidence to suggest that mindfulness could be an effective intervention to reduce psychological distress and support behaviorally- and inflammatory-mediated cvd risk reduction. this project aims to refine and synthesize mindfulness and behavior change content from evidence-based protocols (mindfulness-based stress reduction and diabetes prevention program) to develop and pilot test a new text message-enhanced intervention called "one mind one heart" (om-oh) using feedback from semi-structured interviews with opwh in psychological distress (n=20), and my multidisciplinary mentorship team (aim 1). an open pilot (n=5) with exit interviews and pre-post self-report assessments, will inform the initial acceptability of om-oh and further refine om-oh as needed (aim 2). finally, a pilot randomized controlled trial (rct; n=50) will be conducted to a.) evaluate benchmarks of feasibility and acceptability of study methods and refined om-oh compared to enhanced usual care, and b.) investigate potential for effects on psychological distress, inflammation, and behavioral cvd risk (aim 3). findings will provide the foundation for an r01 application to conduct an efficacy trial of om-oh to reduce inflammatory-mediated cvd risk among opwh.


Eligibility criteria:
inclusion criteria: 1. age ≥50 years 2. clinical diagnosis of hiv per medical record or provision of current antiretroviral medication prescription 3. viral suppression - i.e., lower than detectable limit - per medical record or provision of viral load test from the past six months 4. current elevated psychological distress (score ≥10 on 10-item kessler psychological distress scale \[k10\]) screener) 5. ≥1 cvd risk factor (based on acc/aha atherosclerotic cardiovascular disease risk score calculator; e.g., diabetes, current smoker, hypertension, and high cholesterol 6. access to cell phone with text messaging capabilities exclusion criteria: 1. non-english-speaking 2. cognitive impairments preventing informed consent 3. untreated or under-treated serious mental illness (i.e., psychosis and bipolar disorder) based on clinical interview
patient education in rheumatoid arthritis and osteoarthritis

Conditions: Rheumatoid Arthritis; Osteoarthritis

Summary: this project will evaluate the effectiveness and general usefulness of two arthritis patient education programs. the first, the arthritis self-management program, is a 6-week, community-based program taught in small groups by peer leaders. the second, the self-managed arthritis relief therapy (smart) program, is a computer-driven program delivered through the mail. participants in this project are people with rheumatoid arthritis or osteoarthritis who are taking part in the larger long-term studies being conducted by aramis (the arthritis, rheumatism and aging medical information system).

in a changing health care environment, the role of patients in managing their arthritis is increasingly important. patient education is the primary means for teaching patients how to fulfill this role successfully. the goal of self-management health education is not merely to provide information but also to change patient attitudes and behavior so that patient outcomes are improved. these programs represent a new treatment for arthritis. this project will evaluate the relative effect on health status and cost-effectiveness of two arthritis patient education programs that use different delivery systems. the arthritis self-management program (asmp) uses a small group, multi-class format. it is taught by trained lay leaders and has been evaluated for effectiveness and widely disseminated. the self-managed arthritis relief therapy (smart) program is a computer-driven, individualized, mail-delivered intervention. results of a pilot study suggest that it is effective in improving health status and reducing health care use. the project will also evaluate how generalizable the smart program is and its effectiveness for patients with different diagnoses (oa and ra). it will also determine the attributes of patients who choose and do not choose to participate in patient education programs as well as the attributes of those who complete and do not complete the asmp and smart programs. through use of the aramis data collection system, the project allows us to describe the differences between people who volunteer to receive patient education and those who refuse patient education. this project is directed at improving patient outcomes in both ra and oa through wide availability of a low-cost, mail-delivered arthritis self-management program that is the next generation in arthritis health education.

Eligibility criteria:
inclusion criteria: * physician diagnosis of oa or ra * participation in the aramis longitudinal study exclusion criteria: * age under 18

Keywords: rheumatoid arthritis (ra) osteoarthritis (oa) arthritis education health care service evaluation outcomes research arthritis self-management program (asmp) self-managed arthritis relief therapy (smart) program